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In the original publication, ADA treatment values mentioned in the results section, under the heading 'Study Outcomes' were published incorrectly.

The correct text should read "Additionally, compared to PSP users, PSP non-users had significantly lower percentage of patients that started at PAM-13 level 4 at baseline and remained at level 4 until week 78 of ADA treatment (52.4% vs 28.9%, *p* = 0.001)".

The online version of the original article can be found under doi:10.1007/s40744-017-0061-7.
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